TrueMark-MSI-Assay-for-MSI-Analysis

Easier, more comprehensive microsatellite instability testing

Using as little as 2 ng of FFPE-derived DNA, the new Applied Biosystems TrueMark MSI Assay has a panel of 13 microsatellite markers to test for MSI associated with Lynch syndrome-related cancers beyond colorectal cancer and study immuno-therapy. The included analysis and reporting software featuring automated calling can potentially help you make decisions faster.

See app note

What is microsatellite instability and why is it important?

Microsatellite instability (MSI) is the condition of genetic hypermutability that results from impaired DNA mismatch repair (MMR). Studies indicate that the presence of high levels of MSI (MSI-H) might be predictive of Lynch syndrome, a hereditary condition associated with increased cancer risk across a variety of tumor types, including colorectal, gastric, and endometrial cancers.

Defects in MMR also result in novel somatic mutations in unrelated loci throughout the genome. These mutations can produce immunogenic proteins that can “prime” an immune response to the foreign neoantigens in the tumor. MSI-H tumors are potentially more sensitive to immune checkpoint inhibitor treatment than microsatellite-stable (MSS) tumors, making MSI analysis across diverse tumors important for the identification of those whose growth might be slowed by immunotherapy treatments.

Easier MSI testing

The TrueMark MSI Assay is a low-input, affordable assay with an expanded 13-MSI-marker panel and includes TrueMark MSI Analysis Software. The entire workflow takes as little as four hours to determine sample status. TrueMark MSI Analysis Software features automated calling, which can potentially accelerate accurate decision-making. The TrueMark MSI Assay leverages a 6-dye set to incorporate the additional markers and does not require the use of a tumor-normal match, cutting the number of wells required per sample in half and reducing sample handling burden.

Features of the TrueMark MSI Assay include:

  • Automated calling—simple analysis and reporting software includes automated calling of markers and samples
  • Optional normal control—no requirement to use tumor-normal match for interpretation
  • Expanded panel—13 microsatellite markers (including the Bethesda panel) to test for MSI associated with Lynch syndrome-related cancers and to study immuno-therapy
  • Low input—use as little as 2 ng FFPE-derived DNA
  • Rapid workflow—go from extracted DNA to results in as little as four hours with less than one hour of hands-on time
  • Existing workflow compatibility—designed to run on the SeqStudio and 3500 Series genetic analyzers

PG1994-PJT4846-COL33297-MSI-Assay-New-AppNote1-Global-FLR-1

Application Note: TrueMark MSI Assay—a simplified solution for analyzing microsatellite instability in FFPE tumor samples

This application note describes the development of our new MSI analysis solution that includes an expanded 13-MSI-marker panel and two highly variable STR sequences that can be used to track sample identity. It has been optimized for use on the SeqStudio and 3500 Series genetic analyzers. In addition, we developed software for analyzing the assay that does not require side-by-side analysis of normal, non-tumor tissue. Learn more about the new TrueMark MSI Assay by downloading our application note.

Download app note


Simple MSI data analysis and reporting software

Included at no additional cost, TrueMark MSI Analysis Software is designed specifically for the TrueMark MSI Assay to enable automated calling of markers and samples, offering greater ease of analysis by reducing the manual QC, analysis, and review required to determine sample status.

Learn more and download the TrueMark MSI Analysis Software ›